



US009636359B2

(12) **United States Patent**
Kenyon et al.

(10) **Patent No.:** **US 9,636,359 B2**
(45) **Date of Patent:** **May 2, 2017**

(54) **PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT**

(75) Inventors: **Julian Norman Kenyon**, Hampshire (GB); **Paul Rodney Clayton**, Surrey (GB); **David Tosh**, Bath and North East Somerset (GB); **Fernando Felquer**, Glenside (AU); **Ralf Brandt**, Greenwith (AU)

(73) Assignee: **The University of Sydney**, New South Wales (AU)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/502,917**

(22) PCT Filed: **Oct. 22, 2010**

(86) PCT No.: **PCT/AU2010/001403**

§ 371 (c)(1),

(2), (4) Date: **Jun. 22, 2012**

(87) PCT Pub. No.: **WO2011/047434**

PCT Pub. Date: **Apr. 28, 2011**

(65) **Prior Publication Data**

US 2012/0251516 A1 Oct. 4, 2012

(30) **Foreign Application Priority Data**

Oct. 22, 2009 (AU) 2009905147

Jun. 17, 2010 (AU) 2010902655

(51) **Int. Cl.**

A61K 33/04 (2006.01)

A61K 31/095 (2006.01)

(Continued)

(52) **U.S. Cl.**

CPC **A61K 33/04** (2013.01); **A61K 31/095** (2013.01); **A61K 31/21** (2013.01); **A61K 38/47** (2013.01); **A61K 38/4826** (2013.01); **A61K 45/06** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,514,388 A * 4/1985 Psaledakis 424/94.1
4,978,332 A * 12/1990 Luck A61K 33/24
514/930

(Continued)

FOREIGN PATENT DOCUMENTS

KR 2007/0012040 1/2007
WO WO 2009/061051 * 5/2009

OTHER PUBLICATIONS

Novak JF et al, Proenzyme Therapy of Cancer, Anticanc Res 25: 1157-1178, 2005).*

(Continued)


Primary Examiner — Erin M Bowers

(74) *Attorney, Agent, or Firm* — Carol L. Francis; Khin K. Chin; Bozicevic, Field & Francis LLP


(57) **ABSTRACT**

The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumor cell to enhance cell-to-cell adhesion of tumor cells, effect proteolysis of tumor cells, or induce tumor cell

(Continued)



Caco2 cell standard curve



HEK293 cell standard curve